Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Oxford BioMedica enters collaboration and license agreement with Bioverativ in hemophilia

Feb. 15, 2018

Lee's licenses development and commercialization rights to GCC-4401C in China and SE Asia

Feb. 14, 2018

Phase III quality of life data reported for turoctocog alfa pegol in hemophilia A

Feb. 12, 2018

uniQure presents further clinical data on AMT-060 for hemophilia B

Feb. 9, 2018

SPK-8011 shown safe and effective for hemophilia A

Feb. 9, 2018

Rebinyn launched in the U.S.for the treatment of hemophilia B

Feb. 9, 2018

Novel PAR-4 antagonists discovered at Bristol-Myers Squibb

Feb. 7, 2018

FDA expands indication for AMAG's Feraheme

Feb. 6, 2018

Acticor Biotech's phase I study of ACT-017 meets endpoints

Feb. 6, 2018

Phase III AEGIS-CKD study of Feraccru does not meet primary endpoint

Feb. 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...